Clinical trials: Salmonella Typhi Infection
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in subjects from various age groups in India and Pakistan where Typhoid Fever is highly endemic and an efficacious vaccine…
- Trial name
- NCT01229176
- Testing
- Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine
- Where
- 2 sites in India, Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Ebola Virus Disease, Malaria
Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
A mobile suitcase laboratory for EBOV point-of-care (POC) detection at Ebola treatment centers was successfully implemented in Guinea during the large Ebola virus disease (EVD) outbreak in West-Africa 2014-2015.
- Conditions
- Ebola Virus Disease, Malaria, Typhoid Fever, Dengue Fever
- Trial name
- MobEboDRC (NCT04235361)
- Testing
- Differential RPA tests
- Where
- 4 sites in Canada, Democratic Republic of the Congo and 2 more
- Volunteers
- 500 people
- Sponsor
- University of Stirling
Hepatitis A
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi.
- Trial name
- NCT00197249
- Testing
- Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid Fever
Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine
This study will evaluate a new (conjugate) vaccine for typhoid fever, which remains a serious disease especially difficult to treat in developing countries.
- Trial name
- NCT00277147
- Testing
- BB IND 6989
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Safety Issues, Immunogenicity
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.
- Trial name
- NCT04051268
- Testing
- Vi-DT Typhoid Conjugate Vaccine, PQed Typhoid Conjugate Vaccine, Vi Polysaccharide Vaccine
- Where
- Indonesia
- Volunteers
- 3,071 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Bloodstream Infection, Salmonella Bacteremia
Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are a frequent cause of bloodstream infection, display high levels of antibiotic resistance and have a high case fatality rate (15%).
- Conditions
- Bloodstream Infection, Salmonella Bacteremia, Malaria,Falciparum, Severe Malaria
- Trial name
- DeNTS (NCT04473768)
- Where
- Belgium
- Volunteers
- 1,880 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Major Depressive Disorder
Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients
The purpose of this study is to explore the effect of an inflammatory and a psychosocial stressor and the combination thereof on mood in healthy young and elderly participants and patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01533285
- Testing
- Salmonella typhi vaccine (Typhim Vi)
- Where
- 2 sites in Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Typhoid
Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine
This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose. The study objectives are: I.
- Trial name
- NCT03933098
- Testing
- Test Vaccine Vi-DT Typhoid conjugate, Control Vaccine Typbar TCV®
- Where
- 4 sites in Nepal
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Salmonella Typhi Infection
Understanding How Salmonella Typhi Infects Humans (Bottlenecks)
Typhoid fever is an infection caused by the bacteria Salmonella Typhi (S. Typhi). S. Typhi causes disease principally in developing countries where communities do not have access to safe water or adequate sanitation.
- Trial name
- NCT03889067
- Testing
- Salmonella Typhi challenge
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Inflammation, Vaccine
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
The purpose of this study is to determine if adding dietary fiber, such as inulin, to a diet that does not have enough fiber would raise the levels of potentially beneficial bacteria, such as Bifidobacterium, in the gut.
- Conditions
- Inflammation, Vaccine, Intestinal Permeability, Typhoid Fever
- Trial name
- NCT04543877
- Testing
- Inulin, Maltodextrin, Ty21a Typhoid Fever Vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Typhoid
Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
This study evaluated the persistence of immunity following primary typhoid conjugate vaccination in early childhood and assessed the immunogenicity and safety of a booster dose administered 5-6 years later.
- Trial name
- NCT07624175
- Testing
- Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM
- Where
- Burkina Faso
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Kathleen Neuzil
Enteric Fever
Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
1. Primary Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2.
- Trial name
- NCT07314281
- Testing
- Azithromycin, Meropenem Injection
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Indus Hospital and Health Network
Typhoid, Paratyphoid Fever
Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China
This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131833
- Testing
- Typhoid Vi vaccine, Meningococcal A (control)
- Where
- China
- Volunteers
- 96,468 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125008
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- India
- Volunteers
- 37,673 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Severe Acute Malnutrition in Childhood, Pneumococcal Disease
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.
- Conditions
- Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines, Pneumococcal Infection
- Trial name
- OPTIMAL (NCT06817421)
- Testing
- Pneumococcal conjugate vaccine, Typhoid conjugate vaccine
- Where
- Timor-Leste
- Volunteers
- 214 people
- Sponsor
- Nick Fancourt
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Typhoid Fever
Safety and Immunogenicity of Typhax, a Typhoid Vaccine
This was a randomized, double-blind, ascending dose study conducted at a single clinical research center.
- Trial name
- NCT03926455
- Testing
- Typhax (investigational typhoid fever candidate vaccine), Active Comparator Typhim Vi
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Matrivax Research and Development Corporation
Enteric Fever, Typhoid Fever
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
The investigators aim to compare two antibiotic treatments for enteric (typhoid) fever. Three hundred patients at Patan Hospital will be enrolled in the study.
- Trial name
- NCT01421693
- Testing
- Ceftriaxone, Gatifloxacin
- Where
- 2 sites in Nepal
- Volunteers
- 300 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Typhoid
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
Typhoid fever is an illness that may cause mild effects in children, such as fever and feeling tired, or it may cause serious effects-- even death.
- Trial name
- NCT03614533
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV)
- Where
- Burkina Faso
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore